ECRON ACUNOVA
  Centerwatch | Search
 
 
 
Whitepapers    
     
2010  
June BioSpectrum ranks EA No. 32 amongst top 50 biotech firms of India. No 7 amongst top 20 bioservices firms
  “Offshore, Re-shore or Right-shore: A critical appraisal of risks and opportunities in the emerging markets with focus on India” by Dr. Antal K Hajos presented at 46th DIA Annual Meeting in Washington DC
  Why India’s regulatory environment supports the country as a favoured clinical trials destination and the associated advantages and challenges faced by sponsors in this market. By Dr. B G Jayasheel, Raj Pharma June 2010
  “Potential of Clinical trials in India” by DA Prasanna presented at Bangalore India Bio, 4th June 2010
May “Clinical Development Plan (CDP) – Claim and Feasibility” presented by PD Thomas Bethke, MD & Frank Rathgeb, MD and “Offshoring Using the Example of India – a Survey” presented by Antal K. Hajos, PhD at V. Interdisziplinäres Expertengespräch im PharmaProjekthaus. Reported by Eckhard Böttcher-Bühler at DGPharMed News 2010 | Jahrgang 12 | Heft 2 | Mai (Language: German)
   
 
 
Whitepapers Archive
2009
“How to Conduct Clinical Trials in Germany as a Mid-Size Player” by Dr. Antal K Hajos presented at Germany Trade & Invest Event in Israel
2008
Strategies of the German Pharmaceutical Industry in India – by Matthias Koch, Clemens Paschke, Antal Hajos (Language: German)
2007
"Ethical Considerations in Clinical Trials” at 59th Indian Pharmaceutical Congress - Varanasi, India by Dr.Krathish Bopanna
2005
Indian Pharmaceutical Industry: Vision 2010, CXO Conclave, Manipal
 
Whitepapers
2009
2008
2007
2005
 
  Disclaimer | Privacy Policy